GPX3 and B-cell chronic lymphocytic leukemia: Our data imply that elevated expression of SOD2 and GPX3, as seen in the CLL cybrids (Figure 6), may be reducing ROS production and contributing to the CLL cybrid resistance to ibrutinib treatment.